Literature DB >> 29625788

Clinicopathological and predictive significance of SIRT1 and peroxisome proliferator-activated receptor gamma in esophageal squamous cell carcinoma: The correlation with EGFR and Survivin.

Fei Han1, Suxia Zhang2, Jun Liang2, Weizhe Qiu2.   

Abstract

SIRT1 (silent mating type information regulation 2 homolog 1) is an enzyme that deacetylates proteins that contributes to cell survival and angiogenesis. Peroxisome proliferator-activated receptor Ƴ (PPAR Ƴ) is a member of the nuclear steroid hormone receptor superfamily and regulates cell apoptosis and proliferation. The functional roles of SIRT1 and PPAR Ƴ in tumor progression remain controversy. This study aims to investigate the roles of SIRT1 and PPAR Ƴ in esophageal squamous cell carcinoma (ESCC), as well as correlation with expression of EGFR and Survivin. Here, we analyzed the protein expression of SIRT1 and PPAR Ƴ in tumor microarray with ESCC and its associations with clinicopathological parameters and overall survival. Both SIRT1 and PPAR Ƴ were highly expressed in tumor tissues comparing with non-cancerous epithelium. High expression of SIRT1 was positively correlated with advanced TNM stage and poor outcome, while high expression of PPAR Ƴ was positively related with tumor grading, not with patients' prognosis. In addition, the high expression of SIRT1 was positively correlated with overexpression of EGFR, not related with PPAR Ƴ or Survivin expression status. These data suggests SIRT1 may serve as a predictor of poor prognosis in ESCC, and its mediated tumor-promoting role might be associated with the overexpression of EGFR protein in ESCC.
Copyright © 2018 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  EGFR; ESCC; PPAR Ƴ; SIRT1; Survivin

Mesh:

Substances:

Year:  2018        PMID: 29625788     DOI: 10.1016/j.prp.2018.03.018

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  8 in total

Review 1.  SIRT1 Expression Is a Promising Prognostic Biomarker in Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-analysis.

Authors:  Ryota Otsuka; Haruhito Sakata; Kentaro Murakami; Masayuki Kano; Satoshi Endo; Takeshi Toyozumi; Yasunori Matsumoto; Hiroshi Suito; Masahiko Takahashi; Nobufumi Sekino; Soichiro Hirasawa; Kazuya Kinoshita; Takuma Sasaki; Hisahiro Matsubara
Journal:  Cancer Diagn Progn       Date:  2022-03-03

Review 2.  Role of sirtuins in esophageal cancer: Current status and future prospects.

Authors:  Ryota Otsuka; Koichi Hayano; Hisahiro Matsubara
Journal:  World J Gastrointest Oncol       Date:  2022-04-15

Review 3.  Epigenetic Alterations in Oesophageal Cancer: Expression and Role of the Involved Enzymes.

Authors:  Nair Lopes; Margareta P Correia; Rui Henrique; Carmen Jerónimo
Journal:  Int J Mol Sci       Date:  2020-05-15       Impact factor: 5.923

4.  Association of sirtuin-1 and vascular endothelial growth factor expression with tumor progression and poor prognosis in liposarcoma.

Authors:  Hongzeng Wu; Qianqian Zhang; Yi Zhao; Fengzhou Xu; Jinming Zhang; Hongyan He; Xu Wang; Helin Feng
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

5.  RNA-binding protein RPS3 contributes to hepatocarcinogenesis by post-transcriptionally up-regulating SIRT1.

Authors:  Lijun Zhao; Jianzhong Cao; Kexin Hu; Penghui Wang; Guodong Li; Xiaodong He; Tanjun Tong; Limin Han
Journal:  Nucleic Acids Res       Date:  2019-02-28       Impact factor: 16.971

6.  Overexpression of SIRT1 in urothelial carcinoma of the urinary bladder is associated with local recurrence and poor survival.

Authors:  Jaudah A Al-Maghrabi
Journal:  Saudi Med J       Date:  2019-06       Impact factor: 1.484

7.  Clinical value of SIRT1 as a prognostic biomarker in esophageal squamous cell carcinoma, a systematic meta-analysis.

Authors:  Yu-Ling Zhang; Pei Chen; Ying Guo; Yan-Jun Zhang
Journal:  Open Med (Wars)       Date:  2022-03-14

8.  Expression of SIRT1 and survivin correlates with poor prognosis in esophageal squamous cell carcinoma.

Authors:  Li Yan; Qilong Zhao; Lili Liu; Ning Jin; Shuxia Wang; Xuemei Zhan
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.